Long term survival after whole brain radiotherapy for brain metastasis in follicular dendritic cell sarcoma

Abstract

Figure 7: The widely excised specimenWe conclude that ASPS can remain undetected for a long period and can be easily overlooked due to relative lack of symptoms of the primary tumor. Early metastasis is a characteristic feature of this poor prognostic tumor and unfortunately, in large number of patients, it present with lung or brain metastasis as the first manifestation of the disease. In the cases of occult primary with metastasis to the lungs, ASPS should also be suspected as one of the possibility.

Follicular Dendritic Cell Sarcoma of the Tonsil: A Multimodality Approach

“…Other regimens that were used include those that are used for lymphomas (ifosfamide, carboplatin and etoposide (ICE) [ 11 , 13 , 24 ], dexamethasone, cytarabine and cisplatin (DHAP) [ 9 , 13 ], etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH) [ 10 ], etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) [ 13 , 27 , 30 , 31 ], ifosfamide, gemcitabine, vinorelbine and prednisolone (IGEV) [ 19 ]) and soft tissue sarcomas (doxorubicin, ifosfamide and mesna (AIM) [ 14 , 20 , 21 , 31 ], ifosfamide and etoposide (IE) [ 13 ], gemcitabine and docetaxel (Gem/Doce) [ 13 , 22 , 23 , 32 ]). Notably, all three sarcoma regimens have been demonstrated to induce complete response, with the combination of gemcitabine and docetaxel resulting in complete response in the third-line setting in one case [ 13 ].…”

“…In this scenario, the patient may be spared from chemotherapy and still achieve a long disease-free interval, and possibly have a chance for a cure. The three reported patients [ 21 , 28 , 32 ] who had radiotherapy of localized recurrence remained free of metastatic progression at the time of last follow-up, which extended to as long as 6 years post-treatment for one patient [ 21 ].…”